Effective use of Teliso-V in NSCLC demands adequate sequencing with biomarkers such as MET overexpression, as inappropriate administration in MET-negative tumors may result in no therapeutic benefit but increase toxicity risk, especially pulmonary adverse events (40). Here, MET is linked to non-small cell lung carcinoma.